Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 67,166	$ 72,689
Research and development related success payments and contingent consideration	120	(55,438)
General and administrative	16,766	14,434
Total operating expenses	84,052	31,685
Loss from operations	(84,052)	(31,685)
Interest income, net	1,976	339
Other expense, net	(47)	(102)
Net loss	$ (82,123)	$ (31,448)
Net income (loss) per common share - basic	$ (0.43)	$ (0.17)
Net income (loss) per common share - diluted	$ (0.43)	$ (0.17)
Weighted-average number of common shares - basic	191,228	185,955
Weighted-average number of common shares - diluted	191,228	185,955